OverviewSuggest Edit

Rezolute is a biopharmaceutical company with a platform to develop novel extended release therapies. Our platform combines proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. Rezolute's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $11 billion market where the current standard of care is a once-daily basal insulin injection. We believe that our development strategy increases the probability of technical success while reducing safety and efficacy concerns, approval risks, and overall development costs. We also believe that our approach will result in significantly improved and more efficacious therapies with substantial benefits to the global diabetic population.

TypePublic
Founded2010
HQLouisville, US
Websiterezolutebio.com

Latest Updates

Employees (est.) (Jun 2019)19(-5%)
Share Price (Sept 2020)$0.4 (-3%)
Cybersecurity ratingAMore

Key People/Management at Rezolute

Nevan Charles Elam

Nevan Charles Elam

Chief Executive Officer
Jin Kim

Jin Kim

Chairman
Sankaram Mantripragada

Sankaram Mantripragada

Chief Scientific Officer
Keith Vendola

Keith Vendola

CFO
Gil Labrucherie

Gil Labrucherie

Director
Jung-Hee Lim

Jung-Hee Lim

Director
Show more

Rezolute Office Locations

Rezolute has offices in Louisville, Bend and Redwood City
Louisville, US (HQ)
1450 Infinite Dr
Bend, US
1030 NW Bond St #203
Redwood City, US
201 Redwood Shores Pkwy #315
Show all (3)

Rezolute Financials and Metrics

Rezolute Revenue

USD

Net income (Q3, 2020)

(5.0m)

EBIT (Q3, 2020)

(5.1m)

Market capitalization (23-Sept-2020)

129.1m

Closing stock price (23-Sept-2020)

0.4

Cash (31-Mar-2020)

14.0m

EV

115.5m
Rezolute's current market capitalization is $129.1 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cost of goods sold

1.4m2.4m2.6m1.2m1.2m

General and administrative expense

42.7k67.7k475.0k6.0m5.5m8.2m11.5m6.8m

R&D expense

3.5k34.3k4.7m9.4m12.1m17.3m19.1m

Operating expense total

42.7k71.2k509.4k10.7m15.0m20.3m28.7m25.9m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cost of goods sold

462.4k296.4k620.1k755.5k461.6k511.7k567.4k994.4k426.1k227.6k219.2k72.9k472.6k8.9k187.0k254.0k284.0k

General and administrative expense

7.4k8.0k8.6k9.3k26.3k19.5k7.5k450.8k164.6k1.5m1.0m1.3m1.5m1.4m1.3m1.8m2.0m2.4m2.3m2.5m1.6m1.9m1.9m1.9m1.7m1.3m

R&D expense

3.0k2.2k112.6k1.6m1.3m2.0m2.5m2.3m2.5m3.1m3.4m4.3m3.4m2.5m929.9k1.3m15.1m3.2m5.0m3.7m

Operating expense total

7.4k8.0k8.6k9.3k29.4k19.5k7.5k453.0k277.2k3.1m2.3m3.3m4.1m3.7m3.8m4.9m5.4m6.7m5.8m5.0m2.6m3.2m17.0m5.2m6.7m5.1m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.1k527.05.9m5.3m4.1m4.5m1.6m11.6m

Accounts Receivable

8.8m

Prepaid Expenses

95.5k83.4k320.3k442.0k361.9k571.0k

Inventories

223.0k289.6k67.2k
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(49.3k)(6.7m)(9.7m)(11.4m)(14.9m)(20.3m)(29.9m)(30.4m)

Depreciation and Amortization

221.0295.011.3k134.1k751.3k1.1m1.1m49.0k

Inventories

(66.6k)222.4k

Accounts Payable

(1.1k)80.1k272.0k436.7k26.4k112.3k824.5k(548.0k)
USDQ1, 2012

Financial Leverage

1.3 x
Show all financial metrics

Rezolute Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Rezolute Online and Social Media Presence

Embed Graph

Rezolute News and Updates

Rezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting

REDWOOD CITY, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT) recently announced that it has validated pharmacokinetic (PK) and pharmacodynamic (PD) models of its lead clinical asset, RZ358. Phase 2a data in adult and pediatric patients with cong…

Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism

REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical trial of its lead candidate, RZ358, in patients with congenital hyperinsulinism (CHI). The Company ha…

Rezolute to Present at BIO CEO & Investor Conference 2020

REDWOOD CITY, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming presentation regarding the company’s clinical development in rare disease at the BIO CEO & Investor Conference 2020, to be held in New York, NY on Febr…

Rezolute Management to Present at 2020 Biotech Showcase Conference

REDWOOD CITY, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2020 Biotech Showcase Conference in San Francisco on Monday, January 13, 2020 at 9:00 a.m. PT. 

Rezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors

REDWOOD CITY, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a biopharmaceutical company specializing in the development of innovative drug therapies for patients with metabolic diseases, announced today the appointment of Gil Labrucherie to it…

Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million

REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, announced today that it has entered into a $25 m…
Show more

Rezolute Blogs

Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes

REDWOOD CITY, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT) today announced top-line results from its Phase 1 trial of AB101, an ultra-long acting basal insulin for potential use in patients with type 1 and type 2 diabetes. AB101 was administer…

Rezolute Management to Present at 2019 BIO Investor Forum Conference

REDWOOD CITY, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 BIO Investor Forum Conference in San Francisco on Tuesday, October 22, 2019 at 9:00 a.m. PT.  The audio portion of the pr…

Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option

REDWOOD CITY, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative therapies targeting metabolic and orphan diseases, announced today that Handok, Inc. (“Handok”) and Genexi…
Show more

Rezolute Frequently Asked Questions

  • When was Rezolute founded?

    Rezolute was founded in 2010.

  • Who are Rezolute key executives?

    Rezolute's key executives are Nevan Charles Elam, Jin Kim and Sankaram Mantripragada.

  • How many employees does Rezolute have?

    Rezolute has 19 employees.

  • Who are Rezolute competitors?

    Competitors of Rezolute include Diabetology, Oramed Pharmaceuticals and Diapin Therapeutics.

  • Where is Rezolute headquarters?

    Rezolute headquarters is located at 1450 Infinite Dr, Louisville.

  • Where are Rezolute offices?

    Rezolute has offices in Louisville, Bend and Redwood City.

  • How many offices does Rezolute have?

    Rezolute has 3 offices.